BRPI0807578A2 - macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético - Google Patents

macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético Download PDF

Info

Publication number
BRPI0807578A2
BRPI0807578A2 BRPI0807578-6A BRPI0807578A BRPI0807578A2 BR PI0807578 A2 BRPI0807578 A2 BR PI0807578A2 BR PI0807578 A BRPI0807578 A BR PI0807578A BR PI0807578 A2 BRPI0807578 A2 BR PI0807578A2
Authority
BR
Brazil
Prior art keywords
alkyl
macrocycle
methyl
compound
peptidomimetic macrocycle
Prior art date
Application number
BRPI0807578-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Huw M. Nash
Original Assignee
Aileron Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics, Inc. filed Critical Aileron Therapeutics, Inc.
Publication of BRPI0807578A2 publication Critical patent/BRPI0807578A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0807578-6A 2007-02-23 2008-02-25 macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético BRPI0807578A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90307307P 2007-02-23 2007-02-23
US60/903,073 2007-02-23
PCT/US2008/054922 WO2008104000A2 (en) 2007-02-23 2008-02-25 Triazole macrocycle systems

Publications (1)

Publication Number Publication Date
BRPI0807578A2 true BRPI0807578A2 (pt) 2021-06-15

Family

ID=39710801

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807578-6A BRPI0807578A2 (pt) 2007-02-23 2008-02-25 macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético

Country Status (10)

Country Link
US (6) US7981999B2 (OSRAM)
EP (4) EP3301108A1 (OSRAM)
JP (2) JP4997293B2 (OSRAM)
CN (3) CN104086641A (OSRAM)
AU (1) AU2008218116B2 (OSRAM)
BR (1) BRPI0807578A2 (OSRAM)
CA (1) CA2678941C (OSRAM)
ES (3) ES2398310T3 (OSRAM)
IL (2) IL200532A (OSRAM)
WO (1) WO2008104000A2 (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
EP2489360A1 (en) 2006-11-15 2012-08-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
CN105061577A (zh) * 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN104086641A (zh) 2007-02-23 2014-10-08 爱勒让治疗公司 三唑大环系统
CA2682174C (en) * 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
CA2685568A1 (en) * 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of treating diabetes using bad bh3 domain peptide
WO2009110952A2 (en) * 2007-12-31 2009-09-11 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
AU2014201269B2 (en) * 2008-02-08 2016-09-15 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
CN104474529A (zh) * 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
US20090326192A1 (en) * 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110250685A1 (en) * 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
WO2010033617A2 (en) * 2008-09-16 2010-03-25 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
EP2331567A1 (en) * 2008-09-22 2011-06-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737916A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034032A2 (en) * 2008-09-22 2010-03-25 Aileron Therapeutic, Inc. Methods for preparing purified polypeptide compositions
EP2334697A1 (en) * 2008-09-22 2011-06-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737922A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20120101047A1 (en) * 2008-09-22 2012-04-26 Aileron Therapetics Inc. Peptidomimetic macrocycles
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP5677980B2 (ja) * 2009-01-23 2015-02-25 パシフィック・サイエンティフィック・エナジェティック・マテリアルズ・カンパニー 鉛フリー起爆薬の調合
ES2512717T3 (es) * 2009-02-27 2014-10-24 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos para el tratamiento de la retinitis pigmentosa
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2011047215A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
US9073969B2 (en) 2009-11-16 2015-07-07 Centre National de la Recherche Scientifique—CNRS Compounds and methods for purifying peptides produced by solid phase peptide synthesis
US9227995B2 (en) * 2010-04-23 2016-01-05 Øyvind Jacobsen Peptides
WO2012021875A1 (en) * 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012051405A1 (en) 2010-10-13 2012-04-19 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
EP2651964B1 (en) 2010-12-15 2018-02-28 The Research Foundation of State University of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
WO2012173846A2 (en) * 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
WO2013062923A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2013071039A1 (en) * 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
CA2864120A1 (en) * 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
US9278984B2 (en) 2012-08-08 2016-03-08 Pacific Scientific Energetic Materials Company Method for preparation of a lead-free primary explosive
SMT202100337T1 (it) 2012-09-26 2021-07-12 Harvard College Peptidi graffati bloccati con prolina e loro usi
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
JP6568515B2 (ja) 2013-03-13 2019-08-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
CN105492460A (zh) 2013-06-14 2016-04-13 哈佛大学的校长及成员们 稳定化多肽胰岛素受体调控剂
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
JP6603668B2 (ja) * 2013-10-28 2019-11-06 ノーレックス インコーポレイテッド Ｎｍｄａ受容体モジュレーター及びプロドラッグ、塩、並びにこれらの使用
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3145523A4 (en) 2014-05-21 2018-02-21 President and Fellows of Harvard College Ras inhibitory peptides and uses thereof
ES2987765T3 (es) * 2014-09-11 2024-11-18 Seagen Inc Suministro dirigido de sustancias farmacéuticas que contienen amina terciaria
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) * 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017218949A2 (en) * 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
EP4043479A1 (en) 2016-09-30 2022-08-17 FUJIFILM Corporation Cyclic peptide, affinity chromatography support, labeled antibody, antibody-drug conjugate, and pharmaceutical preparation
CN111601803A (zh) 2017-09-08 2020-08-28 西雅图基因公司 微管溶素及其中间体的制备方法
AU2018385697B2 (en) 2017-12-15 2023-11-09 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11286299B2 (en) * 2018-09-17 2022-03-29 Massachusetts Institute Of Technology Peptides selective for Bcl-2 family proteins
EP4352088A1 (en) 2021-06-09 2024-04-17 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000259A (en) * 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
AU3439589A (en) 1988-03-24 1989-10-16 Terrapin Diagnostics, Inc. Molecular sticks for controlling protein conformation
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
WO1994025482A1 (en) 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US6287787B1 (en) * 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5675001A (en) * 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
DE69521815T2 (de) 1995-05-04 2002-04-04 The Scripps Research Institute, La Jolla Proteinsynthese mittels nativer chemischer ligation (07.01.97)
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5849954A (en) * 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
EP1015479A4 (en) 1997-04-11 2002-07-24 Lilly Co Eli COMBINATIVE SUBSTANCE LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND THE RELATED METHODS
EP1015578A4 (en) 1997-09-17 2004-12-01 Walker And Eliza Hall Inst Of THERAPEUTIC MOLECULES
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
CA2363077A1 (en) 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
WO2000058361A1 (en) 1999-03-29 2000-10-05 The Procter & Gamble Company Melanocortin receptor ligands
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
AU2002252246A1 (en) 2001-03-09 2002-09-24 University Of Louisville Helicomimetics and stabilized lxxll peptidomimetics
US20040106548A1 (en) 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
WO2003057158A2 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
IL162604A0 (en) 2002-01-03 2005-11-20 Yissum Res Dev Co Conformationally constrained c-backbone cyclic peptides
AU2003211093A1 (en) 2002-02-15 2003-09-09 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US20030166138A1 (en) * 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
ES2346646T5 (es) 2002-05-30 2018-02-15 The Scripps Research Institute Ligación catalizada con cobre de azidas y acetilenos
EP1541692A1 (en) 2002-09-06 2005-06-15 Kaneka Corporation PROCESS FOR PRODUCING L-a-METHYLCYSTEINE DERIVATIVE
JP2006516383A (ja) 2002-09-09 2006-07-06 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３ペプチドおよびその使用方法
SI1562941T1 (sl) 2002-11-07 2010-05-31 Kosan Biosciences Inc Trans dehidroepotilon c in d njihovi analogi in postopek za izdelavo le teh
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
AU2003902743A0 (en) 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides
WO2005007675A2 (en) * 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE ϵ-AMINO ACIDS
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
DE602004014170D1 (de) * 2003-10-03 2008-07-10 Merck & Co Inc Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
US20070207947A1 (en) 2003-10-16 2007-09-06 Aplagen Gmbh Stabilized Peptides
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
EP1602663A1 (en) * 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
CN100335467C (zh) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 一锅法区域选择性合成5－碘代－1，4－二取代－1，2，3－三氮唑化合物
ES2326750T3 (es) * 2004-10-29 2009-10-19 Schering Corporation 5-carboxiamido pirazoles y (1,2,4) triazoles como agentes antivirales.
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20080213175A1 (en) * 2006-09-15 2008-09-04 Kolb Hartmuth C Click chemistry-derived cyclic peptidomimetics as integrin markers
EP2489360A1 (en) 2006-11-15 2012-08-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN104086641A (zh) 2007-02-23 2014-10-08 爱勒让治疗公司 三唑大环系统
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
CA2685568A1 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of treating diabetes using bad bh3 domain peptide
WO2009110952A2 (en) 2007-12-31 2009-09-11 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CN104474529A (zh) * 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20090326192A1 (en) 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
US20110250685A1 (en) 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
BRPI0919414A2 (pt) 2008-09-18 2017-07-11 Univ New York Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737916A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2334697A1 (en) 2008-09-22 2011-06-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2331567A1 (en) 2008-09-22 2011-06-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20120101047A1 (en) 2008-09-22 2012-04-26 Aileron Therapetics Inc. Peptidomimetic macrocycles
WO2010034032A2 (en) 2008-09-22 2010-03-25 Aileron Therapeutic, Inc. Methods for preparing purified polypeptide compositions
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2011047215A1 (en) 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
CA2828889A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013033645A1 (en) 2011-08-31 2013-03-07 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US20170037086A1 (en) 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR20180022971A (ko) 2015-07-02 2018-03-06 다나-파버 캔서 인스티튜트 인크. 안정화된 항미생물성 펩티드
US20170037105A1 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3344275B8 (en) 2015-09-03 2023-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
KR20180128022A (ko) 2016-03-21 2018-11-30 에일러론 테라퓨틱스 인코포레이티드 펩티드 모방 거대고리에 대한 동반 진단 도구
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
WO2017218949A2 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Also Published As

Publication number Publication date
US20160304564A1 (en) 2016-10-20
EP2114428A2 (en) 2009-11-11
IL241729A0 (en) 2015-11-30
JP6046686B2 (ja) 2016-12-21
AU2008218116B2 (en) 2012-04-05
CN101663044A (zh) 2010-03-03
US10030049B2 (en) 2018-07-24
IL241729A (en) 2017-09-28
US20080262200A1 (en) 2008-10-23
ES2649941T3 (es) 2018-01-16
CN109627287A (zh) 2019-04-16
EP2564863A2 (en) 2013-03-06
US20110263815A1 (en) 2011-10-27
EP2564863A3 (en) 2013-07-03
ES2398310T3 (es) 2013-03-15
US9957296B2 (en) 2018-05-01
US9023988B2 (en) 2015-05-05
CA2678941C (en) 2018-11-27
AU2008218116A1 (en) 2008-08-28
EP2114428A4 (en) 2010-03-31
EP2564863B1 (en) 2017-08-23
EP2114428B1 (en) 2012-10-31
JP5657594B2 (ja) 2015-01-21
US7981999B2 (en) 2011-07-19
US9493509B2 (en) 2016-11-15
JP4997293B2 (ja) 2012-08-08
JP2012144555A (ja) 2012-08-02
WO2008104000A3 (en) 2008-11-27
CA2678941A1 (en) 2008-08-28
JP2015107966A (ja) 2015-06-11
JP2010519318A (ja) 2010-06-03
EP3301108A1 (en) 2018-04-04
EP2564862A2 (en) 2013-03-06
EP2564862A3 (en) 2013-07-10
EP2564862B1 (en) 2017-08-02
US20160031936A1 (en) 2016-02-04
WO2008104000A2 (en) 2008-08-28
US20160289274A1 (en) 2016-10-06
ES2648687T3 (es) 2018-01-05
US20120190818A1 (en) 2012-07-26
CN104086641A (zh) 2014-10-08
US8637686B2 (en) 2014-01-28
CN101663044B (zh) 2014-07-23
IL200532A (en) 2015-10-29
IL200532A0 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
BRPI0807578A2 (pt) macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético
EP2342222B1 (en) Peptidomimetic macrocycles
EP2094721B1 (en) Bis-sulfhydryl macrocyclization systems
AU2012203906A1 (en) Triazole macrocycle systems

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2633 DE 22-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.